apl. Prof. Dr. Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male - Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial (2022) Koehm M, Foldenauer AC, Rossmanith T, Kellner H, Kiltz U, Rech J, Burmester G, et al. Conference contribution Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients (2022) Raimondo MG, Pachowsky M, Xu C, Rauber S, Tascilar K, Labinsky H, Vogg M, et al. Conference contribution Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting (2022) Birkner B, Rech J, Edelmann E, Verheyen F, Schett G, Stargardt T Journal article Towards preventive treatment of rheumatoid arthritis (2022) Rech J, Schett G Journal article LONG-TERM SAFETY OF CANAKINUMAB IN PATIENTS WITH AUTOINFLAMMATORY DISEASES - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Kuemmerle-Deschner JB, Henes J, Kortus-Goetze B, Kallinich T, Oommen P, Rech J, Krickau T, et al. Conference contribution ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution THE FMF&AID SURVEY - A PATIENT ORGANIZATION DRIVEN SURVEY FOR AUTOINFLAMMATORY DISEASES (2022) Rech J, Tascilar K, Tufan A, Gattorno M, Kuemmerle-Deschner JB, Ozen S, Krickau T, et al. Conference contribution EFFICACY OF UST IN ACTIVE PSA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL (2022) Koehm M, Rossmanith T, Foldenauer AC, Kellner H, Kiltz U, Rech J, Burmester GR, et al. Conference contribution SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL (2022) Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Oommen P, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB Conference contribution